- Home
- RPTX vs CUE Comparison
RPTX vs CUE Comparison
Compare RPTX & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- CUE
- Stock Information
- Founded
- RPTX 2016
- CUE 2014
- Country
- RPTX Canada
- CUE United States
- Employees
- RPTX N/A
- CUE N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- RPTX Health Care
- CUE Health Care
- Exchange
- RPTX Nasdaq
- CUE Nasdaq
- Market Cap
- RPTX 58.8M
- CUE 58.9M
- IPO Year
- RPTX 2020
- CUE 2018
- Fundamental
- Price
- RPTX $1.36
- CUE $0.63
- Analyst Decision
- RPTX Strong Buy
- CUE Strong Buy
- Analyst Count
- RPTX 3
- CUE 3
- Target Price
- RPTX $4.50
- CUE $3.00
- AVG Volume (30 Days)
- RPTX 190.7K
- CUE 163.7K
- Earning Date
- RPTX 05-13-2025
- CUE 05-12-2025
- Dividend Yield
- RPTX N/A
- CUE N/A
- EPS Growth
- RPTX N/A
- CUE N/A
- EPS
- RPTX N/A
- CUE N/A
- Revenue
- RPTX $1,073,000.00
- CUE $7,991,000.00
- Revenue This Year
- RPTX N/A
- CUE N/A
- Revenue Next Year
- RPTX N/A
- CUE $25.99
- P/E Ratio
- RPTX N/A
- CUE N/A
- Revenue Growth
- RPTX N/A
- CUE 13.83
- 52 Week Low
- RPTX $0.89
- CUE $0.45
- 52 Week High
- RPTX $4.29
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- RPTX 55.96
- CUE 37.72
- Support Level
- RPTX $1.33
- CUE $0.61
- Resistance Level
- RPTX $1.41
- CUE $0.71
- Average True Range (ATR)
- RPTX 0.06
- CUE 0.06
- MACD
- RPTX -0.01
- CUE -0.00
- Stochastic Oscillator
- RPTX 55.56
- CUE 17.84
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.